Advaxis (NASDAQ:ADXS) has been given a $19.00 price target by Cantor Fitzgerald in a note issued to investors on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on ADXS. BidaskClub raised shares of Advaxis from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Advaxis in a report on Friday, September 15th.

Shares of Advaxis (NASDAQ:ADXS) opened at $3.00 on Friday. The company has a market cap of $124.86, a PE ratio of -1.30 and a beta of 1.95. Advaxis has a fifty-two week low of $2.71 and a fifty-two week high of $10.06.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The business had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million. analysts predict that Advaxis will post -2.21 EPS for the current fiscal year.

In related news, CFO Sara Bonstein sold 12,734 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the sale, the chief financial officer now directly owns 244,504 shares of the company’s stock, valued at $779,967.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,872,291 shares of company stock worth $8,163,810. Insiders own 7.21% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Voya Investment Management LLC raised its stake in Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 2,975 shares in the last quarter. Northern Capital Management LLC raised its stake in Advaxis by 14.6% in the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 2,650 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Advaxis by 18.2% in the second quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 4,000 shares in the last quarter. Stonebridge Capital Management Inc. grew its position in Advaxis by 88.7% during the third quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 20,045 shares during the last quarter. Finally, State of Wisconsin Investment Board bought a new position in Advaxis during the second quarter valued at approximately $201,000. 41.90% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Advaxis (ADXS) PT Set at $19.00 by Cantor Fitzgerald” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/24/advaxis-adxs-pt-set-at-19-00-by-cantor-fitzgerald.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.